The convergence of bioengineering and advanced materials science has catalyzed groundbreaking innovations in renal replacement therapies, most notably in the development of the electronic kidney (e-kidney). Central to the functionality of this compact, wearable filtration system is the integration of in situ chemical processing mechanisms that emulate the nuanced biochemical regulation of the human nephron. Unlike conventional dialysis, which relies on passive diffusion and ultrafiltration, the e-kidney employs microfluidic arrays embedded with chemically responsive membranes and catalytic nanostructures to selectively modulate ionic fluxes, neutralize metabolic toxins, and maintain electrolyte homeostasis in real time. These chemical processing units dynamically adjust pH levels, scavenge uremic solutes, such as urea and indoxyl sulfate through enzymatic cascades (e.g., urease-functionalized surfaces), and regenerate buffering agents via electrochemically driven cycles. By harnessing selective ion-exchange polymers and redox-active mediators, the system achieves precision filtration while minimizing energy consumption and biofouling. This abstract explores the molecular logic underpinning chemical processing in e-kidney filtration, emphasizing the role of smart materials in transforming passive clearance into active physiological mimicry. The ultimate vision is an adaptive e‑kidney that learns a patient’s metabolic rhythms. By integrating biosensors that stream real‑time concentrations of urea, electrolytes, and pH to an onboard micro‑processor, the device can dynamically adjust enzyme activity, membrane voltage, and NO release. Imagine a system that anticipates a post‑meal potassium surge and pre‑emptively ramps up potassium clearance – much like a smart thermostat maintaining temperature.

🔒 This is a subscription article

Full text is available to subscribers and institutional members. Please choose an option below to access it.

1. Leatherby RJ, Theodorou C, Dhanda R. Renal physiology: Blood flow, glomerular filtration and plasma clearance. Anaesth Intensive Care Med. 2021;22(7):439–442.
2. Daehn IS, Duffield JS. The glomerular filtration barrier: A structural target for novel kidney therapies. Nat Rev Drug Discov. 2021;20(10):770–788.
3. Komers R, Diva U, Inrig JK, Loewen A, Trachtman H, Rote WE. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2020;5(4):494–502.
4. Lehmann DF, Eggleston WD, Wang D. Validation and clinical utility of the hERG IC50:Cmax ratio to determine the risk of drug-induced torsades de pointes: A meta-analysis. Pharmacotherapy. 2018;38(3):341–348.
5. Su Q, Hu F, Ge X, Lei J, Yu S, Wang T, et al. Structure of the human PKD1-PKD2 complex. Science. 2018;361(6406):eaat9819.
6. De Ruyck J, Brysbaert G, Blossey R, Lensink MF. Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinform Chem. 2016;9:1–11.
7. Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: Advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19(12):839–859.
8. Petrosyan A, Cravedi P, Villani V, Angeletti A, Manrique J, Renieri A, et al. A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. Nat Commun. 2019;10(1):3656.
9. Xiong L, Garfinkel A, Barrows K, Brown L, Porat-Shliom N, Deeds EJ. Functional coupling of cellular metabolism and renal hemodynamics underlies kidney sex differences. Physiology (Bethesda). 2025;40(S1):0755.
10. Bakran A, Hopcraft L, Howse M, Edwards SW. The effect of immuno-suppressant drugs on innate immunity: 1467. Transplantation. 2008 Jul 27;86(2 Suppl):491.

The convergence of bioengineering and advanced materials science has catalyzed groundbreaking innovations in renal replacement therapies, most notably in the development of the electronic kidney (e-kidney). Central to the functionality of this compact, wearable filtration system is the integration of in situ chemical processing mechanisms that emulate the nuanced biochemical regulation of the human nephron. Unlike conventional dialysis, which relies on passive diffusion and ultrafiltration, the e-kidney employs microfluidic arrays embedded with chemically responsive membranes and catalytic nanostructures to selectively modulate ionic fluxes, neutralize metabolic toxins, and maintain electrolyte homeostasis in real time. These chemical processing units dynamically adjust pH levels, scavenge uremic solutes, such as urea and indoxyl sulfate through enzymatic cascades (e.g., urease-functionalized surfaces), and regenerate buffering agents via electrochemically driven cycles. By harnessing selective ion-exchange polymers and redox-active mediators, the system achieves precision filtration while minimizing energy consumption and biofouling. This abstract explores the molecular logic underpinning chemical processing in e-kidney filtration, emphasizing the role of smart materials in transforming passive clearance into active physiological mimicry. The ultimate vision is an adaptive e‑kidney that learns a patient’s metabolic rhythms. By integrating biosensors that stream real‑time concentrations of urea, electrolytes, and pH to an onboard micro‑processor, the device can dynamically adjust enzyme activity, membrane voltage, and NO release. Imagine a system that anticipates a post‑meal potassium surge and pre‑emptively ramps up potassium clearance – much like a smart thermostat maintaining temperature.

🔒 This is a subscription article

Full text is available to subscribers and institutional members. Please choose an option below to access it.

1. Leatherby RJ, Theodorou C, Dhanda R. Renal physiology: Blood flow, glomerular filtration and plasma clearance. Anaesth Intensive Care Med. 2021;22(7):439–442.
2. Daehn IS, Duffield JS. The glomerular filtration barrier: A structural target for novel kidney therapies. Nat Rev Drug Discov. 2021;20(10):770–788.
3. Komers R, Diva U, Inrig JK, Loewen A, Trachtman H, Rote WE. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2020;5(4):494–502.
4. Lehmann DF, Eggleston WD, Wang D. Validation and clinical utility of the hERG IC50:Cmax ratio to determine the risk of drug-induced torsades de pointes: A meta-analysis. Pharmacotherapy. 2018;38(3):341–348.
5. Su Q, Hu F, Ge X, Lei J, Yu S, Wang T, et al. Structure of the human PKD1-PKD2 complex. Science. 2018;361(6406):eaat9819.
6. De Ruyck J, Brysbaert G, Blossey R, Lensink MF. Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinform Chem. 2016;9:1–11.
7. Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: Advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19(12):839–859.
8. Petrosyan A, Cravedi P, Villani V, Angeletti A, Manrique J, Renieri A, et al. A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. Nat Commun. 2019;10(1):3656.
9. Xiong L, Garfinkel A, Barrows K, Brown L, Porat-Shliom N, Deeds EJ. Functional coupling of cellular metabolism and renal hemodynamics underlies kidney sex differences. Physiology (Bethesda). 2025;40(S1):0755.
10. Bakran A, Hopcraft L, Howse M, Edwards SW. The effect of immuno-suppressant drugs on innate immunity: 1467. Transplantation. 2008 Jul 27;86(2 Suppl):491.